Skip to main content Accessibility help

We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.

Close cookie message
×
Hostname: page-component-84b7d79bbc-g7rbq Total loading time: 0 Render date: 2024-07-27T12:09:37.982Z Has data issue: false hasContentIssue false

Chapter 12 - Prevention of Acute Graft-versus-Host Disease − One Size Fits All?

from Section 4 - Early Post-Transplant Interval

Published online by Cambridge University Press:  24 May 2017

By
Nelson J. Chao  and
Michael Green
Edited by
Hillard M. Lazarus ,
Robert Peter Gale ,
Armand Keating ,
Andrea Bacigalupo ,
Reinhold Munker  and
Kerry Atkinson
Edited in association with
Syed Ali Abutalib
Hillard M. Lazarus
Affiliation:
Case Western Reserve University, Ohio
Robert Peter Gale
Affiliation:
Imperial College London
Armand Keating
Affiliation:
University of Toronto
Andrea Bacigalupo
Affiliation:
Ospedale San Martino, Genoa
Reinhold Munker
Affiliation:
Louisiana State University, Shreveport
Kerry Atkinson
Affiliation:
University of Queensland
Syed Ali Abutalib
Affiliation:
Midwestern Regional Medical Center, Cancer Treatment Centers of America, Chicago
Get access
Type
Chapter
Information
Hematopoietic Cell Transplants
Concepts, Controversies and Future Directions
 , pp. 105 - 111
Publisher: Cambridge University Press
Print publication year: 2000

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Barrett, AJ, Le Blanc, K. Prophylaxis of acute GVHD: manipulate the graft or the environment? Best Practice & Research Clinical Haematology. 2008;21(2):165–76.CrossRefGoogle ScholarPubMed
Wysocki, CA, Panoskaltsis-Mortari, A, Blazar, BR, Serody, JS. Leukocyte migration and graft-versus-host disease. Blood. 2005;105(11):4191–9.CrossRefGoogle ScholarPubMed
Goker, H, Haznedaroglu, IC, Chao, NJ. Acute graft-vs-host disease: pathobiology and management. Experimental Hematology. 2001;29(3):259–77.CrossRefGoogle ScholarPubMed
Alousi, AM, Bolanos-Meade, J, Lee, SJ. Graft-versus-host disease: state of the science. Biology of Blood and Marrow Transplantation: Journal of the American Society for Blood and Marrow Transplantation. 2013;19(1 Suppl):S102–8.CrossRefGoogle ScholarPubMed
Al-Kadhimi, Z, Gul, Z, Chen, W, Smith, D, Abidi, M, Deol, A, et al. High incidence of severe acute graft-versus-host disease with tacrolimus and mycophenolate mofetil in a large cohort of related and unrelated allogeneic transplantation patients. Biology of Blood and Marrow Transplantation: Journal of the American Society for Blood and Marrow Transplantation. 2014;20(7):979–85.CrossRefGoogle Scholar
Sung, AD, Chao, NJ. Acute graft-versus-host disease: are we close to bringing the bench to the bedside? Best Practice & Research Clinical Haematology. 2013;26(3):285–92.CrossRefGoogle Scholar
Ferrara, JL, Levine, JE, Reddy, P, Holler, E. Graft-versus-host disease. Lancet. 2009;373(9674):1550–61.CrossRefGoogle ScholarPubMed
Ruutu, T, van Biezen, A, Hertenstein, B, Henseler, A, Garderet, L, Passweg, J, et al. Prophylaxis and treatment of GVHD after allogeneic haematopoietic SCT: a survey of centre strategies by the European Group for Blood and Marrow Transplantation. Bone Marrow Transplantation. 2012;47(11):1459–64.CrossRefGoogle ScholarPubMed
Hamad, N, Del Bel, R, Messner, HA, Kim, D, Kuruvilla, J, Lipton, JH, et al. Outcomes of hematopoietic cell transplantation in adult patients with acquired aplastic anemia using intermediate dose alemtuzumab-based conditioning. Biology of Blood and Marrow Transplantation: Journal of the American Society for Blood and Marrow Transplantation. 2014;20(11):1722–8.CrossRefGoogle ScholarPubMed
Kanda, J, Long, GD, Gasparetto, C, Horwitz, ME, Sullivan, KM, Chute, JP, et al. Reduced-intensity allogeneic transplantation using alemtuzumab from HLA-matched related, unrelated, or haploidentical related donors for patients with hematologic malignancies. Biology of Blood and Marrow Transplantation: Journal of the American Society for Blood and Marrow Transplantation. 2014;20(2):257–63.CrossRefGoogle ScholarPubMed
Grullich, C, Ziegler, C, Finke, J. Rabbit anti T-lymphocyte globulin induces apoptosis in peripheral blood mononuclear cell compartments and leukemia cells, while hematopoetic stem cells are apoptosis resistant. Biology of Blood and Marrow Transplantation: Journal of the American Society for Blood and Marrow Transplantation. 2009;15(2):173–82.CrossRefGoogle ScholarPubMed
Bacigalupo, A, Lamparelli, T, Bruzzi, P, Guidi, S, Alessandrino, PE, di Bartolomeo, P, et al. Antithymocyte globulin for graft-versus-host disease prophylaxis in transplants from unrelated donors: 2 randomized studies from Gruppo Italiano Trapianti Midollo Osseo (GITMO). Blood. 2001;98(10):2942–7.CrossRefGoogle ScholarPubMed
Finke, J, Bethge, WA, Schmoor, C, Ottinger, HD, Stelljes, M, Zander, AR, et al. Standard graft-versus-host disease prophylaxis with or without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated donors: a randomised, open-label, multicentre phase 3 trial. The Lancet Oncology. 2009;10(9):855–64.CrossRefGoogle ScholarPubMed
Soiffer, RJ, Lerademacher, J, Ho, V, Kan, F, Artz, A, Champlin, RE, et al. Impact of immune modulation with anti-T-cell antibodies on the outcome of reduced-intensity allogeneic hematopoietic stem cell transplantation for hematologic malignancies. Blood. 2011;117(25):6963–70.CrossRefGoogle ScholarPubMed
Theurich, S, Fischmann, H, Shimabukuro-Vornhagen, A, Chemnitz, JM, Holtick, U, Scheid, C, et al. Polyclonal anti-thymocyte globulins for the prophylaxis of graft-versus-host disease after allogeneic stem cell or bone marrow transplantation in adults. The Cochrane Database of Systematic Reviews. 2012;9:CD009159.Google Scholar
Luznik, L, Bolanos-Meade, J, Zahurak, M, Chen, AR, Smith, BD, Brodsky, R, et al. High-dose cyclophosphamide as single-agent, short-course prophylaxis of graft-versus-host disease. Blood. 2010;115(16):3224–30.CrossRefGoogle ScholarPubMed
Luznik, L, O’Donnell, PV, Symons, HJ, Chen, AR, Leffell, MS, Zahurak, M, et al. HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide. Biology of Blood and Marrow Transplantation: Journal of the American Society for Blood and Marrow Transplantation. 2008;14(6):641–50.CrossRefGoogle ScholarPubMed
Reshef, R, Luger, SM, Hexner, EO, Loren, AW, Frey, NV, Nasta, SD, et al. Blockade of lymphocyte chemotaxis in visceral graft-versus-host disease. The New England Journal of Medicine. 2012;367(2):135–45.CrossRefGoogle ScholarPubMed
Ram, R, Storb, R. Pharmacologic prophylaxis regimens for acute graft-versus-host disease: past, present and future. Leukemia & Lymphoma. 2013;54(8):1591–601.CrossRefGoogle ScholarPubMed
Koreth, J, Stevenson, KE, Kim, HT, McDonough, SM, Bindra, B, Armand, P, et al. Bortezomib-based graft-versus-host disease prophylaxis in HLA-mismatched unrelated donor transplantation. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology. 2012;30(26):3202–8.CrossRefGoogle ScholarPubMed
Kraut, EH, Neff, JC, Bouroncle, BA, Gochnour, D, Grever, MR. Immunosuppressive effects of pentostatin. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology. 1990;8(5):848–55.CrossRefGoogle ScholarPubMed
Parmar, S, Andersson, BS, Couriel, D, Munsell, MF, Fernandez-Vina, M, Jones, RB, et al. Prophylaxis of graft-versus-host disease in unrelated donor transplantation with pentostatin, tacrolimus, and mini-methotrexate: a phase I/II controlled, adaptively randomized study. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology. 2011;29(3):294–302.CrossRefGoogle ScholarPubMed
Dinarello, CA, Fossati, G, Mascagni, P. Histone deacetylase inhibitors for treating a spectrum of diseases not related to cancer. Molecular Medicine. 2011;17(5–6):333–52.CrossRefGoogle Scholar
Choi, SW, Braun, T, Chang, L, Ferrara, JL, Pawarode, A, Magenau, JM, et al. Vorinostat plus tacrolimus and mycophenolate to prevent graft-versus-host disease after related-donor reduced-intensity conditioning allogeneic haemopoietic stem-cell transplantation: a phase 1/2 trial. The Lancet Oncology. 2014;15(1):87–95.CrossRefGoogle Scholar
Zeiser, R, Youssef, S, Baker, J, Kambham, N, Steinman, L, Negrin, RS. Preemptive HMG-CoA reductase inhibition provides graft-versus-host disease protection by Th-2 polarization while sparing graft-versus-leukemia activity. Blood. 2007;110(13):4588–98.CrossRefGoogle ScholarPubMed
Hamadani, M, Gibson, LF, Remick, SC, Wen, S, Petros, W, Tse, W, et al. Sibling donor and recipient immune modulation with atorvastatin for the prophylaxis of acute graft-versus-host disease. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology. 2013;31(35):4416–23.CrossRefGoogle ScholarPubMed
Pillai, AB, George, TI, Dutt, S, Strober, S. Host natural killer T cells induce an interleukin-4-dependent expansion of donor CD4+CD25+Foxp3+ T regulatory cells that protects against graft-versus-host disease. Blood. 2009;113(18):4458–67.CrossRefGoogle ScholarPubMed
Lowsky, R, Takahashi, T, Liu, YP, Dejbakhsh-Jones, S, Grumet, FC, Shizuru, JA, et al. Protective conditioning for acute graft-versus-host disease. The New England Journal of Medicine. 2005;353(13):1321–31.CrossRefGoogle ScholarPubMed
Kohrt, HE, Turnbull, BB, Heydari, K, Shizuru, JA, Laport, GG, Miklos, DB, et al. TLI and ATG conditioning with low risk of graft-versus-host disease retains antitumor reactions after allogeneic hematopoietic cell transplantation from related and unrelated donors. Blood. 2009;114(5):1099–109.CrossRefGoogle ScholarPubMed
Messina, G, Giaccone, L, Festuccia, M, Irrera, G, Scortechini, I, Sorasio, R, et al. Multicenter experience using total lymphoid irradiation and antithymocyte globulin as conditioning for allografting in hematological malignancies. Biology of Blood and Marrow Transplantation: Journal of the American Society for Blood and Marrow Transplantation. 2012;18(10):1600–7.CrossRefGoogle ScholarPubMed
Ringden, O, Pihlstedt, P, Markling, L, Aschan, J, Baryd, I, Ljungman, P, et al. Prevention of graft-versus-host disease with T-cell depletion or cyclosporin and methotrexate. A randomized trial in adult leukemic marrow recipients. Bone Marrow Transplantation. 1991;7(3):221–6.Google ScholarPubMed
Wagner, JE, Thompson, JS, Carter, SL, Kernan, NA, members of the Unrelated Donor Marrow Transplantation Trial. Effect of graft-versus-host disease prophylaxis on 3-year disease-free survival in recipients of unrelated donor bone marrow (T-cell Depletion Trial): a multi-centre, randomised phase II-III trial. Lancet. 2005;366(9487):733–41.CrossRefGoogle Scholar
Pavletic, SZ, Carter, SL, Kernan, NA, Henslee-Downey, J, Mendizabal, AM, Papadopoulos, E, et al. Influence of T-cell depletion on chronic graft-versus-host disease: results of a multicenter randomized trial in unrelated marrow donor transplantation. Blood. 2005;106(9):3308–13.CrossRefGoogle ScholarPubMed
Pasquini, MC, Devine, S, Mendizabal, A, Baden, LR, Wingard, JR, Lazarus, HM, et al. Comparative outcomes of donor graft CD34+ selection and immune suppressive therapy as graft-versus-host disease prophylaxis for patients with acute myeloid leukemia in complete remission undergoing HLA-matched sibling allogeneic hematopoietic cell transplantation. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology. 2012;30(26):3194–201.CrossRefGoogle ScholarPubMed
Cutler, C, Logan, B, Nakamura, R, Johnston, L, Choi, S, Porter, D, et al. Tacrolimus/sirolimus versus tacrolimus/methotrexate as GVHD prophylaxis after matched, related donor allogeneic hematopoietic cell transplantation. Blood. 2014;124(8):1372–7.CrossRefGoogle Scholar

Save book to Kindle

To save this book to your Kindle, first ensure coreplatform@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

Available formats
×